Literature DB >> 9425600

The P-glycoprotein efflux pump: how does it transport drugs?

F J Sharom1.   

Abstract

Pgp is an atypical translocating ATPase, with low affinity for ATP and high constitutive ATPase activity. Pgp also has an unusually broad specificity for hydrophobic substrates, including many chemotherapeutic drugs. Transport studies in reconstituted systems indicate that drug transport requires ATP hydrolysis and is active, generating a drug concentration gradient. Binding of drugs and ATP to Pgp induces conformational changes in the protein, and the drug binding site is conformationally coupled to the NBDs. Evidence accumulated to date suggests that the transporter interacts directly with nonpolar substrates within the membrane environment, and may act as a drug flippase, moving drugs from the inner to the outer leaflet of the bilayer. Chemosensitizers that block the action of Pgp are proposed to act as alternative substrates, but their high rate of spontaneous flip-flop across the membrane results in futile cycling of the transporter.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9425600     DOI: 10.1007/s002329900305

Source DB:  PubMed          Journal:  J Membr Biol        ISSN: 0022-2631            Impact factor:   1.843


  78 in total

Review 1.  The impact of efflux transporters in the brain on the development of drugs for CNS disorders.

Authors:  Eve M Taylor
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Structure and function of efflux pumps that confer resistance to drugs.

Authors:  M Ines Borges-Walmsley; Kenneth S McKeegan; Adrian R Walmsley
Journal:  Biochem J       Date:  2003-12-01       Impact factor: 3.857

Review 3.  Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders.

Authors:  Gloria Lee; Reina Bendayan
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

Review 4.  Efflux transporters as a novel herbivore countermechanism to plant chemical defenses.

Authors:  Jennifer S Sorensen; M Denise Dearing
Journal:  J Chem Ecol       Date:  2006-05-23       Impact factor: 2.626

5.  Pharmacokinetic consequences of active drug efflux at the blood-brain barrier.

Authors:  Stina Syvänen; Rujia Xie; Selma Sahin; Margareta Hammarlund-Udenaes
Journal:  Pharm Res       Date:  2006-04-07       Impact factor: 4.200

6.  Effects of acylcarnitines on efflux transporting system in Caco-2 cell monolayers.

Authors:  Mikio Tomita; Nobuyuki Doi; Masahiro Hayashi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2010-09       Impact factor: 2.441

7.  Recognition of sulfonylurea receptor (ABCC8/9) ligands by the multidrug resistance transporter P-glycoprotein (ABCB1): functional similarities based on common structural features between two multispecific ABC proteins.

Authors:  Anis Bessadok; Elisabeth Garcia; Hélène Jacquet; Solenne Martin; Alexia Garrigues; Nicolas Loiseau; François André; Stéphane Orlowski; Michel Vivaudou
Journal:  J Biol Chem       Date:  2010-11-22       Impact factor: 5.157

8.  Synergy between verapamil and other multidrug -resistance modulators in model membranes.

Authors:  Madeleine Castaing; Alain Loiseau; Athel Cornish-Bowden
Journal:  J Biosci       Date:  2007-06       Impact factor: 1.826

9.  Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation.

Authors:  Hazem E Hassan; Alan L Myers; Andrew Coop; Natalie D Eddington
Journal:  J Pharm Sci       Date:  2009-12       Impact factor: 3.534

Review 10.  The mechanism of action of multidrug-resistance-linked P-glycoprotein.

Authors:  Z E Sauna; M M Smith; M Müller; K M Kerr; S V Ambudkar
Journal:  J Bioenerg Biomembr       Date:  2001-12       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.